3 Reasons Why Growth Investors Shouldn't Overlook Bristol Myers (BMY)Zacks Investment Research • 08/03/20
Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple MyelomaBusiness Wire • 07/29/20
Bristol-Myers Squibb Shows Improved Relative Strength; Still Shy Of BenchmarkInvestors Business Daily • 07/20/20
Is Bristol Myers (BMY) a Solid Growth Stock? 3 Reasons to Think " Yes "Zacks Investment Research • 07/17/20
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Lisocabtagene Maraleucel (liso-cel)Business Wire • 07/17/20
Bristol Myers Squibb Announces Expiration and Final Results of Registered Exchange OffersBusiness Wire • 07/16/20
These 3 Patient Advocacy Groups Are Helping Solve Issues in the COVID-19 PandemicThe Motley Fool • 07/12/20
Bristol Myers (BMY) Moves to Strong Buy: Rationale Behind the UpgradeZacks Investment Research • 07/09/20